Skip to main content

Cardiac Amyloidosis

2
Pipeline Programs
6
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%
+ 7 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Attralus
AttralusFL - Naples
1 program
1
I-124 evuzamitidePhase 3Peptide
Bayer
BayerLEVERKUSEN, Germany
1 program
1
I-124 evuzamitidePhase 3Peptide1 trial
Active Trials
NCT06788535Completed204Est. Apr 2026
Pfizer
PfizerNEW YORK, NY
3 programs
Cardiac amyloidosis deep learning modelN/A
International Cardiac Amyloidosis RegistryN/A1 trial
diagnostic algorithmN/A1 trial
Active Trials
NCT06894290Recruiting300Est. Jul 2026
NCT04459169Unknown424Est. Dec 2021
Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
2 programs
Florbetaben F18PHASE_11 trial
[18F]florbetabenPHASE_31 trial
Active Trials
NCT06790394Recruiting15Est. Sep 2026
NCT05184088Recruiting200Est. Mar 2026
BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
Cardiac amyloidosis deep learning modelN/A1 trial
Active Trials
NCT06469372Completed50Est. Aug 2025
Providence Therapeutics
1 program
EchoNet-LVH AssessmentN/A1 trial
Active Trials
NCT06664866Enrolling By Invitation500Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerI-124 evuzamitide
Life Molecular Imaging[18F]florbetaben
Life Molecular ImagingFlorbetaben F18
Providence TherapeuticsEchoNet-LVH Assessment
BridgeBio PharmaCardiac amyloidosis deep learning model
PfizerInternational Cardiac Amyloidosis Registry
Pfizerdiagnostic algorithm

Clinical Trials (7)

Total enrollment: 1,693 patients across 7 trials

NCT06788535BayerI-124 evuzamitide

REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

Start: Jan 2025Est. completion: Apr 2026204 patients
Phase 3Completed
NCT05184088Life Molecular Imaging[18F]florbetaben

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Start: Jan 2023Est. completion: Mar 2026200 patients
Phase 3Recruiting
NCT06790394Life Molecular ImagingFlorbetaben F18

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

Start: Oct 2025Est. completion: Sep 202615 patients
Phase 1Recruiting
NCT06664866Providence TherapeuticsEchoNet-LVH Assessment

AI Echocardiographic Screening of Cardiac Amyloidosis

Start: Oct 2024Est. completion: Nov 2026500 patients
N/AEnrolling By Invitation
NCT06469372BridgeBio PharmaCardiac amyloidosis deep learning model

Cardiac Amyloidosis Discovery Trial

Start: May 2024Est. completion: Aug 202550 patients
N/ACompleted
NCT06894290PfizerInternational Cardiac Amyloidosis Registry

International Cardiac Amyloidosis Registry

Start: Jun 2023Est. completion: Jul 2026300 patients
N/ARecruiting
NCT04459169Pfizerdiagnostic algorithm

Cardiac Amyloidosis : Diagnostic Using Red Flag Signals

Start: Sep 2020Est. completion: Dec 2021424 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 1,693 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.